USO 23049
A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GDC-6036 IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH A KRAS G12C MUTATION. (BO44426)
Disease Types: Lung Cancer Research
Eligibility Requirements:
• Unresectable advanced or metastatic NSCLC.
• Validated tissue or blood testing of KRAS G12C+.
• No prior treatment for advanced unresectable or metastaticNSCLC.
• Prior therapy for non-metastatic disease is allowed if patient
presents at least 12 months of treatment-free interval before
study enrollment.
• PD-L1 expression ≥1% in tumor tissue.
• Pre-treatment tumor tissue report must be provided.
• No other oncogenic driver with available targeted
treatment .
For more information on this trial CLICK HERE .
Available at: